Amanta Healthcare Limited — Q1FY27 Earnings Call Summary

AMANTA · Q1FY27 · Filed 08 Aug 2026

Key Takeaways

• SteriPort platform now 44% of revenue; capacity expanding from 6.6 Cr to 12 Cr bottles/year, commissioning delayed to Q2 FY27
• Captive 10.8 MW solar power plant commissioned June 2026, expected to reduce power costs and improve margins
• Q1 FY27 revenue INR69 Cr, +5% y-y; EBITDA margin ~22%
• SVP facility to start operations by Q4 FY27, focusing on export markets with high-margin products
• FY27 SteriPort Line 3 peak revenue expected INR110-120 Cr annualized, with EBITDA margin expansion of 4-5% including solar savings
• FY28 peak revenue target INR425 Cr with EBITDA margin 25-26%
• Working capital days ~141 due to quarantine requirements; debt expected to reduce by INR30-35 Cr annually
• Incremental depreciation from new lines approx INR6 Cr annually
• Focus on sterile dosage forms with pipeline of 20 products in inhalation, ophthalmics, and diluents for advanced markets
• Incremental ROCE for SteriPort line ~16-17%, SVP ~14-15%; effective tax rate ~26%

📄 Source: View original transcript (PDF)

Summary generated by AI from the official transcript filed on BSE/NSE. Not investment advice.